Latest news with #ESCMIDGlobal2025
Korea Herald
03-05-2025
- Business
- Korea Herald
Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation
SEOUL, South Korea, May 2, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, has attracted strong interest after the company presented a conceptual video of its CURECA TM at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria. Industry professionals recognized CURECA TM as a promising advancement in automating the entire PCR diagnostic workflow — from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025. More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene's booth to view the conceptual video introducing the CURECA TM. "It was evident that the Seegene booth attracted considerable attention at ESCMID," said one professional from academia. Experts Recognize CURECA TM as a Game Changer in Molecular Testing Automation The CURECA TM is designed to automate the entire PCR diagnostic process. It can handle various specimen types required in the pre-treatment stage in MDx – such as stool, urine, blood, and sputum—as well as perform the complete PCR testing workflow following sample loading. The following are select comments from industry professionals who previewed Seegene's CURECA TM at ESCMID Global 2025: "I hold high expectations for the fully automated PCR molecular diagnostics, as CURECA TM not only eliminates human error inherent in manual processes but also enables efficient testing without time or workforce constraints." "We often encounter specimen types that require careful and time-consuming manual pre-processing. A system that can automate this step could represent a true paradigm shift. This level of automation is transformative – a real game changer – and unlike any existing solution. I eagerly await its launch." "If paired with our in-house diagnostic tool kits, CURECA TM could offer a complete synergy. I hope CURECA TM will be accessible to small and mid-sized facilities." "I'm planning to attend ADLM 2025 in Chicago in July to see the actual device and explore potential collaborations." Customizable Pre-Treatment System Offers Versatility for Future Laboratory Automation The first component of CURECA TM is the Customizable Pre-treatment System (CPS). The CPS is designed to automate the loading of primary sample tubes and operate pre-treatment processing. "The CPS is a modular, automated system intended to streamline pre-treatment processing across diverse diagnostic fields including molecular diagnostics such as PCR, as well as clinical chemistry and immunology assays," said Young-Seag Baeg, Head of Strategy and Planning at Seegene. Numerous healthcare (or laboratory) professionals at ESCMID Global 2025 noted that the conceptual video of CURECA TM showcased the potential of fully automated diagnostic laboratories capable of managing complex workflows associated with pre-treatment. In particular, there was consensus among participants that the CPS, which automates specimen preprocessing, is positioned to bring a significant advancement in in vitro diagnostics as it addresses limitations associated with existing manual procedures that are dependent on trained laboratory professionals. "The turnaround time (TAT) is expected to improve with CURECA TM as the integrated software is capable of adjusting workflows based on reporting deadlines," said a director of a laboratory in Spain. "In particular, for sexually transmitted infections (STIs), the CPS will markedly enhance daily laboratory operations. The processing of specimens for STIs involves manual handling of multiple sample tubes, which contributes to operator fatigue. The adoption of the CPS has the potential to be transformational in streamlining routine operations." Modular and Configurable Solution Design for Tailored Diagnostics Following specimen preprocessing, molecular diagnostics typically involve nucleic acid extraction, PCR setup and amplification, and analysis of results. For specimens that do not need preprocessing, Seegene offers the Primary Sample Aliquot System (PAS) as an alternative to the CPS. PAS is designed to allow direct loading and dispensing of primary samples, helping to simplify the workflow. Seegene is pursuing the integration of PAS with a fully automated PCR process through a modular solution concept called CEFA (Customizable & Expandable Full Automation), intended to support diverse laboratory needs with greater flexibility. Seegene aims to leverage the modular architecture of CURECA TM to support a wide range of diagnostic applications. "CURECA TM can be deployed as a comprehensive system or as individual modules—CPS, PAS, and CEFA—configured independently or in combination to accommodate diverse operational needs," said Baeg. Optimizing Lab Workflows Through Space-Saving Design Another key advantage of the CURECA TM 's modular architecture is that it is designed to adapt to different laboratory spaces and layouts. Its flexible design is intended to allow labs to configure the system according to their specific needs, which Seegene sees as essential for enhancing operational efficiency. Laboratory professionals at ESCMID 2025 shared the following perspectives: "The ability to configure a system to meet specific spatial and operational needs of individual laboratories represents a novel and highly compelling approach." "We expect such flexibility will make it possible to implement workflows that deliver high-quality results with minimal reliance on standardized laboratory configurations and staffing resources." "The enthusiastic global response to our concept video and vision for CURECA TM demonstrate the strong demand for next-generation diagnostic solutions," said Jong-Yoon Chun, CEO of Seegene. "We believe CURECA TM has the potential to catalyze meaningful change in the global PCR diagnostics landscape." Please Note: The comments included in this press release are based on actual interviews and on-site discussions. However, in accordance with requests to protect the privacy of the individuals interviewed, all names have been pseudonimized. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information. Technology-sharing Initiative The technology-sharing initiative aims to globally share Seegene's advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative's ultimate vision is to create "a world free from diseases"—a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness.
Cision Canada
02-05-2025
- Business
- Cision Canada
Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation
Seegene previews a concept video of CURECA TM at ESCMID Global 2025, ahead of its anticipated debut in July With a fully modular design, CURECA TM introduces a bold vision for automating pre-treatment across diverse PCR specimen types Developed for future integration into unattended workflows and adaptable laboratory settings SEOUL, South Korea, May 2, 2025 /CNW/ -- Seegene Inc., a global leader in molecular diagnostics (MDx) solutions, has attracted strong interest after the company presented a conceptual video of its CURECA TM at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria. Industry professionals recognized CURECA TM as a promising advancement in automating the entire PCR diagnostic workflow — from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025. More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene's booth to view the conceptual video introducing the CURECA TM. "It was evident that the Seegene booth attracted considerable attention at ESCMID," said one professional from academia. Experts Recognize CURECA TM as a Game Changer in Molecular Testing Automation The CURECA TM is designed to automate the entire PCR diagnostic process. It can handle various specimen types required in the pre-treatment stage in MDx – such as stool, urine, blood, and sputum—as well as perform the complete PCR testing workflow following sample loading. The following are select comments from industry professionals who previewed Seegene's CURECA TM at ESCMID Global 2025: "I hold high expectations for the fully automated PCR molecular diagnostics, as CURECA TM not only eliminates human error inherent in manual processes but also enables efficient testing without time or workforce constraints." "We often encounter specimen types that require careful and time-consuming manual pre-processing. A system that can automate this step could represent a true paradigm shift. This level of automation is transformative – a real game changer – and unlike any existing solution. I eagerly await its launch." "If paired with our in-house diagnostic tool kits, CURECA TM could offer a complete synergy. I hope CURECA TM will be accessible to small and mid-sized facilities." "I'm planning to attend ADLM 2025 in Chicago in July to see the actual device and explore potential collaborations." Customizable Pre-Treatment System Offers Versatility for Future Laboratory Automation The first component of CURECA TM is the Customizable Pre-treatment System (CPS). The CPS is designed to automate the loading of primary sample tubes and operate pre-treatment processing. "The CPS is a modular, automated system intended to streamline pre-treatment processing across diverse diagnostic fields including molecular diagnostics such as PCR, as well as clinical chemistry and immunology assays," said Young-Seag Baeg, Head of Strategy and Planning at Seegene. Numerous healthcare (or laboratory) professionals at ESCMID Global 2025 noted that the conceptual video of CURECA TM showcased the potential of fully automated diagnostic laboratories capable of managing complex workflows associated with pre-treatment. In particular, there was consensus among participants that the CPS, which automates specimen preprocessing, is positioned to bring a significant advancement in in vitro diagnostics as it addresses limitations associated with existing manual procedures that are dependent on trained laboratory professionals. "The turnaround time (TAT) is expected to improve with CURECA TM as the integrated software is capable of adjusting workflows based on reporting deadlines," said a director of a laboratory in Spain. "In particular, for sexually transmitted infections (STIs), the CPS will markedly enhance daily laboratory operations. The processing of specimens for STIs involves manual handling of multiple sample tubes, which contributes to operator fatigue. The adoption of the CPS has the potential to be transformational in streamlining routine operations." Modular and Configurable Solution Design for Tailored Diagnostics Following specimen preprocessing, molecular diagnostics typically involve nucleic acid extraction, PCR setup and amplification, and analysis of results. For specimens that do not need preprocessing, Seegene offers the Primary Sample Aliquot System (PAS) as an alternative to the CPS. PAS is designed to allow direct loading and dispensing of primary samples, helping to simplify the workflow. Seegene is pursuing the integration of PAS with a fully automated PCR process through a modular solution concept called CEFA (Customizable & Expandable Full Automation), intended to support diverse laboratory needs with greater flexibility. Seegene aims to leverage the modular architecture of CURECA TM to support a wide range of diagnostic applications. "CURECA TM can be deployed as a comprehensive system or as individual modules—CPS, PAS, and CEFA—configured independently or in combination to accommodate diverse operational needs," said Baeg. Optimizing Lab Workflows Through Space-Saving Design Another key advantage of the CURECA TM 's modular architecture is that it is designed to adapt to different laboratory spaces and layouts. Its flexible design is intended to allow labs to configure the system according to their specific needs, which Seegene sees as essential for enhancing operational efficiency. Laboratory professionals at ESCMID 2025 shared the following perspectives: "The ability to configure a system to meet specific spatial and operational needs of individual laboratories represents a novel and highly compelling approach." "We expect such flexibility will make it possible to implement workflows that deliver high-quality results with minimal reliance on standardized laboratory configurations and staffing resources." "The enthusiastic global response to our concept video and vision for CURECA TM demonstrate the strong demand for next-generation diagnostic solutions," said Jong-Yoon Chun, CEO of Seegene. "We believe CURECA TM has the potential to catalyze meaningful change in the global PCR diagnostics landscape." Please Note: The comments included in this press release are based on actual interviews and on-site discussions. However, in accordance with requests to protect the privacy of the individuals interviewed, all names have been pseudonimized. About Seegene Seegene has more than 20 years of dedicated experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability to simultaneously test for 14 pathogens that cause similar signs and symptoms in a single tube with quantitative information. Technology-sharing Initiative The technology-sharing initiative aims to globally share Seegene's advanced diagnostic and data analysis technologies, including syndromic real-time PCR and an automated product development system (SGDDS), with a leading company partnered in each country. Partnering companies will collaborate with local scientists and experts to develop diagnostic tests tailored to the needs of their communities and fields, spanning a wide range of human and non-human diseases. The initiative's ultimate vision is to create "a world free from diseases"—a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness. SOURCE Seegene Inc.
Associated Press
12-04-2025
- Health
- Associated Press
Over 3 million children died from AMR-related infections in 2022, major study shows
A landmark study presented today at ESCMID Global 2025 has revealed that over 3 million children worldwide lost their lives in 2022 due to antimicrobial resistance (AMR)-related infections. VIENNA, April 12, 2025 /CNW/ -- The study underscores the urgent need for both regional and global strategies to control paediatric AMR, particularly in high-burden areas such as South-East Asia and Africa. AMR poses a critical threat to children, who are highly vulnerable to infections. Access to new antibiotic formulations is often much more limited for children because of product development delays. The study data found that in 2022 alone, more than 752,000 children in Southeast Asia and 659,000 children in Africa died of AMR-associated complications. Many of these deaths were linked to the use of Watch antibiotics (drugs with a high risk of resistance) and Reserve antibiotics(last-resort treatments for severe, multidrug-resistant infections). Watch and Reserve antibiotics are not intended for first-line treatment and their use should be limited only for those who need them to preserve their effectiveness and reduce the development of resistance. Between 2019 and 2021, the use of Watch antibiotics increased by 160% in Southeast Asia and 126% in Africa. During the same period, the use of Reserve antibiotics rose by 45% in Southeast Asia and 125% in Africa. Globally, of the more than 3 million children's deaths, 2 million were associated with the use of Watch and Reserve antibiotics. 'While the rise in use of Watch and Reserve antibiotics may be necessary in response to the concurrent rise in drug-resistant infections, the sharp rise in use of these drugs presents several serious long-term risks', commented Professor Joseph Harwell, study co-author. 'Their increased use, especially without careful oversight, elevates the risk of resistance and limits future treatment options. If bacteria develop resistance to these antibiotics, there will be few, if any, alternatives for treating multidrug-resistance infections.' Several factors contribute to the severity of AMR in low- and middle-income countries, including overcrowded hospitals, poor sanitation, and weak infection prevention measures that facilitate the spread of resistant pathogens within healthcare settings and communities. Professor Harwell furthered, 'Mortality rates, which are already alarmingly high, will continue to rise significantly, particularly in low- and middle-income countries where access to alternative treatments and advanced medical interventions may be limited. Addressing this issue requires urgent and coordinated action at both the regional and global levels.' View original content: SOURCE ESCMID Global
Associated Press
10-04-2025
- Health
- Associated Press
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today announced that data from several new studies of NUZYRA® (omadacycline) will be presented at ESCMID Global 2025, the Congress of the European Society of Clinical Microbiology and Infectious Diseases, taking place in Vienna, Austria, April 11-15. 'We continue to invest in science as part of our commitment to furthering the medical community's understanding of NUZYRA,' said Randy Brenner, Chief Development and Regulatory Officer of Paratek. 'This week's ESCMID presentations will include data from non-clinical efficacy studies for the treatment and post-exposure prophylaxis of inhalation anthrax and pneumonic plague, supporting NUZYRA's potential use in biodefense. In addition, researchers will share data on skin and soft tissue infections, enterococcal infections, and activity against Acinetobacter baumannii-calcoaceticus complex isolates.' NUZYRA Presentation Details Presentation Title: Omadacycline for skin and soft tissue infections: a multicentre retrospective analysis of efficacy and safety in real-world clinical practice Time/Location: April 13, noon CEST (7:00 a.m. U.S. EST) in poster area in Hall D Abstract #: 04456 Session Title: 02f. Community-acquired skin, soft tissue, bone & joint infections (incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses) Poster #: P1095 Presentation Title: Clinical efficacy and safety of omadacycline in the treatment of enterococcal infections Time/Location: April 13, noon CEST (7:00 a.m. U.S. EST) in poster area in Hall D Abstract #: 03861 Session Title: 02f. Community-acquired skin, soft tissue, bone & joint infections (incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses) Poster #: P1092 Presentation Title: Omadacycline demonstrated efficacy as both therapeutic treatment and post-exposure prophylaxis against inhalation anthrax and pneumonic plague in cynomolgus macaques Time/Location: April 13, noon CEST (7:00 a.m. U.S. EST) in poster area in Hall D Abstract #: 01058 Session Title: 11. Public health & vaccines Poster #: P3784 (The anthrax-related project has been supported in whole or part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under contract number 75A50120C00001.) (The Pneumonic Plague-related project has been funded by the Rapid Acquisition and Investigation of Drugs for Repurposing program within the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense's (JPEO-CBRND) Joint Project Manager for CBRN Medical.) Presentation Title: Activity of omadacycline against multidrug-resistant and molecularly characterised Acinetobacter baumannii-calcoaceticus complex clinical isolates from United States hospitals, 2020–2023 Time/Location: April 14, noon CEST (7:00 a.m. U.S. EST) in poster area in Hall D Abstract #: 02641 Session Title: 03b. Resistance surveillance & epidemiology: Healthcare-associated bacteria Poster #: P1314 About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a privately held pharmaceutical company providing innovative specialty therapies for community care providers and specialists, addressing important medical and public health threats. Paratek's lead product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic indicated for adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek continues to diversify its portfolio to address unmet patient needs. Paratek was acquired in 2023 by B-FLEXION and Novo Holdings. In December 2019, BARDA awarded Paratek a contract (75A50120C00001) that is now valued at up to approximately $304 million. In addition to supporting the development of NUZYRA for both the treatment and prophylaxis of pulmonary anthrax, this contract supports the U.S. onshoring of NUZYRA and manufacturing security requirements; FDA post-marketing requirements associated with the initial NUZYRA approval; and the procurement of up to 10,000 treatment courses of NUZYRA for the treatment of anthrax. For more information, visit or follow us on LinkedIn and X. About NUZYRA NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals and other drug-resistant strains. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline class antibacterial drugs, or to any of the excipients. WARNINGS AND PRECAUTIONS Mortality imbalance was observed in the CABP clinical trial, with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients >65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality. The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline class antibacterial drugs. NUZYRA is structurally similar to other tetracycline class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs. Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs. NUZYRA is structurally similar to tetracycline class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, fixed drug eruption, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected. Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. ADVERSE REACTIONS The most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation. DRUG INTERACTIONS Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA. Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.
